Henry is an associate in the corporate team in the Shanghai office of Kirkland & Ellis International LLP. His practice focuses on mergers and acquisitions, private placement and pre-IPO financing, joint ventures and strategic partnerships, especially in cross-border settings.
Experience
Representative Matters
Since joining Kirkland & Ellis, Henry has been involved in the following:
Suzhou Ribo Life Science Co., Ltd. (Ribo) in its $40 million Series E1 financing
Clover Biopharmaceuticals, Ltd. (HKSE: 2197) in its global offering and listing on the The Stock Exchange of Hong Kong Limited
Airdoc in its Series D financing
Clover Biopharmaceuticals in its Series C financing
EDDA Healthcare and Technology in its financing round
Prior to joining Kirkland & Ellis, Henry has been involved in the following selected transactions:
MicroPort CardioFlow in its pre-IPO financing
IDG Capital as the lead investor in HiFiBiO Therapeutics’ Series C Financing
Alphamab Oncology in its pre-IPO financings
A leading U.S.-based pharmaceutical company’s reverse merger with a company listed on NASDAQ
A leading Chinese textile and apparel company’s acquisition of the advanced textiles business from a global industry leader
A leading Chinese textile and apparel company’s acquisition of a global leading fashion producer and retailer
A Chinese state-owned company’s acquisition of certain wind parks in Greece
A Chinese state-owned company’s strategic cooperation with a German-listed company in the field of solar power technology
A Chinese state-owned company’s acquisition of a U.S. manufacturer of tunnel boring machines
More
Credentials
Admissions & Qualifications
New York
People’s Republic of China (non-practicing)
Languages
Mandarin
English
Education
University of Pennsylvania Law SchoolLL.M.2014
China University of Political Science and LawLL.B.2013
